orlistat

Orlistat (Tetrahydrolipstatin) is a lipase inhibitor and a fatty acid synthase (FASN) inhibitor. Orlistat has been shown to promote weight loss.

Octyl Orlistat, a potential fatty acid synthase (FASN) inhibitor, has demonstrated significant effectiveness in reducing tumor cell proliferation. By targeting FASN and inducing apoptosis, Orlistat is under investigation as an anti-tumor compound. Compared to Cerulenin and C75, Orlistat shows greater inhibitory potency in cell culture and cell lines. In LN229 cells, treatment with 200 µM Orlistat for 48 hours resulted in a 63.9 ± 8.7% reduction in cell growth, while in LT68 cells, the reduction was 76.3 ± 23.7%. Organotypic slice cultures treated with Orlistat exhibited decreased proliferation after Ki67 staining and an increase in caspase-3 cleavage.

(R,S,S,S)-Orlistat is a stereoisomeric derivative of orlistat (Tetrahydrolipstatin; THL) that inhibits three mycobacterial lipid esterases: Ag85C (KI: 16.43 μM), Rv3802 (EC50: 16.2 nM), and Pks13-TE.

Isoleucine orlistat, L- is a bioactive chemical.

Orlistat degradation product is a degradation product of the digestive lipase inhibitor orlistat . It is formed via hydrolytic and thermal degradation as well as digestion by human carboxyl ester lipase.

Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (10 mg kg) decreases serum cholesterol levels and total bod......

TAK-137 is an AMPA receptor enhancer with antidepressant effects. TAK-137 has the ability to improve cognition and could be used to study schizophrenia.